A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis

Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic

(2017) Iliana Doycheva et al.   HEPATOLOGY

High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance

(2017) J Cai et al.   INTERNATIONAL JOURNAL OF OBESITY

The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications

(2017) Anna Alisi et al.   MEDIATORS OF INFLAMMATION

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

(2016) Dorte Glintborg et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome

(2016) D. Macut et al.   HUMAN REPRODUCTION

Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys

(2016) Oyekoya T Ayonrinde et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Niealkoholowe stłuszczenie wątroby u kobiet z zespołem wielotorbielowatych jajników — aspekty kliniczne i metaboliczne oraz polimorfizm genu lipazy lipoproteinowej

(2015) Anna Bohdanowicz-Pawlak et al.   Endokrynologia Polska

Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease

(2015) E Vassilatou et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Are Women With Polycystic Ovarian Syndrome at a High Risk of Non-Alcoholic Fatty Liver Disease? A Meta-Analysis

(2014) Mahdi Ramezani Binabaj et al.   Hepatitis Monthly

Hyperandrogenism Induces a Proinflammatory TNFα Response to Glucose Ingestion in a Receptor-Dependent Fashion

(2014) Frank González et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls

(2014) Justyna Kuliczkowska Plaksej et al.   International Journal of Endocrinology

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

(2013) H. Kahal et al.   CLINICAL ENDOCRINOLOGY

Global Adiposity and Thickness of Intraperitoneal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS)

(2013) Susana Borruel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)

(2013) Ancha Baranova et al.   Journal of Translational Medicine

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

Polycystic Ovary Syndrome with Hyperandrogenism Is Characterized by an Increased Risk of Hepatic Steatosis Compared to Nonhyperandrogenic PCOS Phenotypes and Healthy Controls, Independent of Obesity and Insulin Resistance

(2012) Helen Jones et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

(2011) Mark O. Goodarzi et al.   Nature Reviews Endocrinology

Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome

(2011) L. F. N. Zueff et al.   ULTRASOUND IN OBSTETRICS & GYNECOLOGY

Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)

(2010) Noreen Hossain et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome

(2009) Athina Markou et al.   FERTILITY AND STERILITY

Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome

(2009) E. Vassilatou et al.   HUMAN REPRODUCTION